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Ethnic differencesEthnic differences in bone metabolism have been reported and it has been suggested that these may be partly
due to prolonged exposure to an elevated plasma parathyroid hormone (PTH) concentration or a decreased
sensitivity to PTH. We explored ethnic differences in bone and mineral metabolism by 5 days of oral
phosphate (P) loading to stimulate PTH secretion. Healthy older people from UK (B), The Gambia (G) and
China (C), 15 individuals from each sex and ethnic group, were studied. Blood and urine samples were
collected before and 2 h after P dose on days 1, 4 and 5 and on a control day. The induced changes (%) in PTH
and markers of mineral and bone metabolism after 2 h and over 5 days were examined.
At baseline, PTH, 1,25(OH)2D and bone turnover markers were higher in Gambian subjects than in British and
Chinese subjects (P≤0.01).
2 h after P loading, ionized calcium (iCa) decreased and PTH and plasma P (P) increased in all groups
(P≤0.01, n.s. between groups). Urinary P to creatinine ratio (uP/Cr) increased, the increase being greater in
Chinese subjects than in British and Gambian subjects on days 4 and 5 (P≤0.01). By day 5, fasting iCa was
decreased and P increased in British and Gambian (P≤0.01) but not in Chinese subjects. Fasting PTH and uP/
Cr increased in all groups. There were ethnic differences in changes in bone markers, but the relationship
with changes in PTH was comparable between groups.
In conclusion, ethnic differences in mineral metabolism in response to 5-day P loading were found. Chinese
subjects showed a more rapid renal clearance of P than British and Gambian counterparts and there were
differences between the groups in the skeletal response to P loading, but no evidence was found for
resistance to the resorbing effects of PTH.
© 2009 Elsevier Inc.Open access under CC BY license.IntroductionPopulations differ in fragility fracture risk. Differences in the extent
of loss of bone quantity and material properties during ageing result
from complex interactions between hormone status, genetic traits,
diet and physical activity over the lifespan. Increased parathyroid
hormone (PTH) secretion and bone turnover induced by poor vitamin
D status and/or low calcium (Ca) intake is considered to increase the
risk of osteoporosis in older people [1].
However, we have shown that older Gambian and Chinese
populations with a low incidence of osteoporotic fractures have
elevated plasma PTH associated with low Ca intake and/or poor
vitamin D status [2–5]. In the UK Ca intake is close to recommenda-
tions, there is a winter nadir in vitamin D status but no corresponding
increase in PTH concentration [5,6]. In The Gambia, vitamin D status isrch, Elsie Widdowson Labora-
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license.good because there is ample opportunity for cutaneous vitamin D
synthesis throughout the year, but Ca intake is exceptionally low
(∼300 mg/day) and PTH concentrations are elevated compared to
British adults throughout the year [3,7]. In northern China, vitamin D
status is poor in winter, Ca intake is low, and PTH concentrations are
higher than those of British counterparts [5]. Furthermore, in older
Chinese adults, there is no signiﬁcant inverse association between PTH
concentration and bone mineral status (BMC and BMD), in contrast to
Caucasian adults in Britain and elsewhere [5,8]. Resistance to the bone
resorbing effects of PTH and racial differences in PTH dynamics have
been reported in Black American women [9–11]. All these ﬁndings
have led us to hypothesise that prolonged exposure to elevated PTH in
plasma, either chronically or seasonally, may alter skeletal respon-
siveness to its effects [12].
Oral phosphate (P) has been used by others to stimulate PTH
secretion and investigate the effect of PTH on bone turnover [13], to
test if skeletal responsiveness to PTH differs between ethnic groups.
We conducted a study in healthy older adults in the UK, The Gambia
and China using a similar protocol.
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Subjects
The study was conducted at MRC Human Nutrition Research
(HNR), Cambridge, UK, MRC Keneba, The Gambia, and Shenyang
Medical College, Shenyang, PR China. Cambridge (latitude 52°N) is a
university town in the southeast of England with a temperate climate.
Keneba (latitude 13°N) is a rural village in The Gambia and the climate
is tropical, hot and sunny all year with a wet season from June to
November. Shenyang (latitude 42°N) is an industrial city in the
northeast of China where winter (November–March) is cold and dark
but summer (June–September) is hot and sunny.
Thirty healthy adults (15 men, 15 women) aged 60–75 years were
recruited in each centre. Exclusion criteria were any pathological
disorder or medication known to affect mineral or bone metabolism.
All subjects were ambulatory with normal renal function (fasting
plasma creatinineb115 μmol/l). Subjects in Cambridge (all were of
Caucasian origin) with a hip bone mineral density (BMD)b−2.5 T-
score were excluded. This criterion was not used in Keneba and
Shenyang because there are no appropriate Chinese and Gambian
reference data.
BMD was measured using dual-energy X-ray absorptiometry
(DXA) (GE Lunar, WI, USA, software 4.7e in all centres). Height and
weight were measured, from which the body mass index (BMI) was
calculated. To allow for possible effects of season, subjects were
studied once in February–April and once in July–September. Five
British (2 males, 3 females), 2 Chinese (1 male, 1 female) and 1
Gambian (female) subjects were not available for the second phase.
Ethical approval was given by the Cambridge Local Research Ethics
Committee, the Gambian Government/MRC Laboratories Joint Ethics
Committee and the Academic Committee of Shenyang Medical
College. Informed written consent was obtained from all subjects.
PTH stimulation test
In each phase of the study, subjects took a 1 g dose of elemental P
dissolved in 200 ml water, twice daily (0700–0900 h and 1900–Fig. 1. Study design. (■) Water on control day or 1 g elemental phosphate dose during the 5-
morning phosphate dose.2100 h) for 5 consecutive days (Phosphate-Sandoz, HK Pharma, UK)
(Fig. 1). Each P dose also contained 246 mg potassium and 938 mg
sodium. The stimulation test was preceded within 5 days by a control
day in which 200 ml water only was given (day 0). On days 0, 1, 4, and
5, subjects attended the research centre between 0700–0900 h after
an overnight fast. Individual subjects attended at the same time for
each of their visits. Blood and urine samples were collected on arrival
(timepoint A) and 2 hours (2 h) after consuming thewater ormorning
P dose (timepoint B). Subjects remained sedentary during the 2 h and
drank 500 ml water to standardise ﬂuid intake but no other food or
liquid was consumed.
Dietary Ca and P intakes were assessed in each phase of the study
[7,14,15]. Subjects were requested to keep to their usual diet the week
before and during each stimulation test.
Sample collections and laboratory analyses
Blood samples were collected into tubes containing EDTA or
lithium-heparin. Blood ionized Ca (iCa) was measured in the lithium-
heparin sample (ABL77, Radiometer Medical, USA) within 10 min and
pH 7.4 corrected values were used. The remainder of the sample was
placed on ice, the plasma was separated from cells within 30 min in a
refrigerated centrifuge, and stored at −80 °C. Urine samples were
collected immediately after blood collection. Acidiﬁed (HCl, 10 ml/l,
laboratory reagent grade, SG 1.18, Fisher Scientiﬁc) and non-acidiﬁed
aliquots were stored at −20 °C. All samples from The Gambia and
samples for analysis of vitamin D metabolites from China were
transported on dry ice to Cambridge.
EDTA-plasma was used for analyses of PTH, total N-terminal
propeptide of type 1 procollagen (P1NP), N-mid osteocalcin (OC) and
β-form of cross-linked C-telopeptide of type 1 collagen (CTXβ).
Lithium-heparin plasma was used for all other analyses. Singleton
measurements were made for blood iCa and for those markers
analyzed by Elecsys (see below). All other analyses were conducted in
duplicate. For each analyte, all samples from a single subject were
analyzed in the same run. Plasma total Ca, P and creatinine (Ca, P and
Cr), and urinary Ca, P and Cr (uCa, uP and uCr) was measured by
colorimetric methods (Cambridge: Konelab, Finland; Shenyang:day test. (↑) Blood and urine samples obtained before (A) and 2 h after (B) water or the
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coefﬁcients of variation (CV) were b2.0% and b4.0% respectively. PTH,
P1NP, OC and CTXβwere measured on an automatic analyzer (Elecsys
2010, Roche Diagnostics, USA). Between-assay CV were 4.7%, 3.2%,
3.1% and 4.3% respectively. The OC assay detects both the intact
molecule and N-terminal fragment. Plasma bone alkaline phosphatase
(BALP) and urinary deoxypyridinoline (uDPD)wasmeasured by ELISA
(Metra BAP and DPD EIA kits, Quidel Corporation, USA). Within and
between-assay CV were 2.1% and 7.9% for BALP and 6.3% and 10.0% for
DPD. Plasma 25- (25-OHD) and 1,25-dihydroxyvitamin D (1,25
(OH)2D) were measured by radioimmunoassay (DiaSorin, Stillwater,
MN, USA and IDS, Tyne and Wear, UK respectively). Within and
between-assay CV were 4.1% and 6.1% for 25-OHD, and 7.5% and 9.0%
for 1,25(OH)2D. Concentrations of uCa, uP and uDPD were expressed
as a ratio relative to urinary creatinine (uCr) to adjust for urine volume
(uCa/Cr, uP/Cr and uDPD/Cr).
Assay performance was monitored using kit and in-house controls.
The quality of 25-OHD, 1,25(OH)2D and PTH assays was monitored by
participation in the Vitamin D External Quality Assessment Scheme
(www.deqas.org), and the National External Quality Assessment
Scheme (www.ukneqas.org.uk). Cross-calibrations were conducted
for those assays that were performed in different centres by
measuring in-house control materials, ten aliquots for each analyte.
The difference between the laboratories ranged from 1% to 9%.
Gambian and Chinese values were adjusted to Cambridge values using
the appropriate multiplication factor.
Data-handling and analysis
Statistical analysis was performed using the Linear Model facility
in Data Desk 6.1.1 (Data Description, Ithaca, NY, USA). To permit the
exploration of proportion relationships, variables were converted to
natural logarithms whereby group differences×100 correspond
closely to percentage differences [(difference/mean)×100] [16]. All
percent differences (±SE) presentedwere obtained this way. Baseline
values are presented as mean (±SD) for normally-distributed data,
and as geometric means (95% CI) for skewed data.
The absolute and relative (percentage) changes in each analyte
were examined to investigate the response to P administration.
Because the patterns of change were similar, only percentage (%)
changes are presented for simplicity. The change by 2 h was deﬁned as
the change in a variable from timepoint A (before P dose) to timepoint
B (2 h after) on the same day. The response on day 0 was used to
control for any change that was independent of the effect of
administered P. Thus, change by 2 h (%)=(lnBday (1, 4 or 5)− lnAday
(1,4 or 5))−(lnBday 0− lnAday 0). Change by day 5 (%)was deﬁned as the
difference in fasting values between baseline (mean of timepoint A on
days 0 and 1) and day 5 (timepoint A), calculated as lnA5− lnAbaseline.
The estimated glomerular ﬁltration rate (eGFR) was calculatedTable 1
Characteristics of subjects.
Males
British Gambian Chinese
Age (years) 67.4±3.3 66.5±3.3 64.4±
Height (cm) 174.3±5.4 166.0±8.6bm⁎⁎ 167.2±
Weight (kg) 80.7±12.4 58.5±7.8bm⁎⁎ 71.2±
BMI (kg/m2) 26.5±3.81 21.2±1.57bm⁎⁎ 25.5±
Ca intake (mg/day) 1185±196 367±129bm⁎⁎ 588±
P intake (mg/day) 1692±271 803±264bm⁎⁎ 1303±
Ca:P 0.70±0.08 0.46±0.08bm⁎⁎ 0.45±
Femoral neck BMD (g/cm2) 0.947±0.121 0.916±0.138 0.898±
Femoral trochanter BMD (g/cm2) 0.889±0.113 0.804±0.117 0.824±
Means (±SD). Differences were examined by Scheffé post-hoc tests. Country differences
bm, bf, cm, cf, gm, gf next to a value indicates signiﬁcant difference from counterpart(s) in
Ca and P intakes were assessed on day 0 for each season and were presented as means of t
BMI, body mass index; Ca, calcium; P, phosphorus, BMD, bone mineral density.according to the Cockroft and Gault equation (Traynor et al., 2006)
[39] and the ratio of the maximum tubular reabsorption rate of
phosphate to glomerular ﬁltration rate (TmP/GFR) was calculated
using the formula described by Payne [18] and Barth et al. [17].
Within groups, the signiﬁcance of change from baseline by 2 h and
day 5, and the difference in 2 h change between days 1 and 5 was
examined by Student's paired t-test. Differences between groups were
examined using ANOVA or ANCOVA. Subject, sex, season and agewere
independent variables and subject was nested by sex and group.
Scheffé post-hoc tests were used to test signiﬁcance of differences
between groups in pairs and to minimise the effects of multiple
testing. Multiple linear regression was used to examine the relation-
ship between change in PTH and change in markers of mineral and
bone metabolism. Group differences in Ca concentration were
examined after adjusting for albumin concentration by including it
as an independent variable. All statistical models were set up in a
standardised way by generating a full model, which included all
potential confounders. Any variable of PN0.05 was removed by
backward elimination to provide a parsimonious model. P
values≤0.05 were considered signiﬁcant.
Results
No signiﬁcant seasonal effects were detected in the British or
Gambian groups. A signiﬁcant difference between the two seasons
was found in some of the biochemical markers in the Chinese group.
However, this did not affect the interpretation of the data presented in
this paper and is not described further. There were signiﬁcant
differences between men and women in many baseline character-
istics. However, there were no signiﬁcant group–season or group–sex
interactions identiﬁed for intra-individual changes by 2 h and day 5 in
any biochemical marker. Therefore, except for subject characteristics
and summary information at baseline, the data for each group are
presented with season and gender combined.
Subject characteristics and baseline data
Age, height, weight, BMI, dietary Ca and P intake and hip BMD are
indicated in Table 1. There were signiﬁcant differences in dietary
intakes of Ca and P within sex and between groups. Dietary Ca and P
intakes and Ca:P ratio were higher in British than Chinese and
Gambian subjects (ANOVA P≤0.01). Ca and P intakes were lower in
Gambian than Chinese subjects (P≤0.05). BMI was higher in British
than in Gambian subjects (ANOVA P≤0.001) and higher in Chinese
males than Gambian males (ANOVA P≤0.05).
Compliance as estimated by pill count was 100%. No side effects
were reported, except for mild to moderate diarrhoea in 3 subjects.
There were signiﬁcant differences in baseline P, Cr, TmP/GFR and
uCa/Cr and in the concentrations of other biochemical markers,Females
British Gambian Chinese
4.3 65.7±3.9 67.5±4.1 62.5±3.3gf⁎
5.5bm⁎⁎ 160.7±6.3 157.9±6.4 154.4±4.7bf⁎
9.1bm⁎,gm⁎⁎ 71.6±13.0 55.9±9.8bf⁎⁎ 62.1±8.0bf⁎
3.17gm⁎ 27.6±4.02 22.3±1.57bf⁎⁎ 26.0±2.53
196bm⁎⁎,gm⁎⁎ 1151±242 296±140bf⁎⁎ 509±266bf⁎⁎,gf⁎⁎
263bm⁎⁎,gm⁎⁎ 1517±224 665±269bf⁎⁎ 1029±262cm⁎,bf⁎⁎,gf⁎⁎
0.11bm⁎⁎ 0.76±0.13 0.45±0.12bf⁎⁎ 0.48±0.15bf⁎⁎
0.114 0.833±0.069 0.749±0.094 0.774±0.118
0.116 0.685±0.082 0.647±0.078 0.671±0.084
were examined within gender group and sex differences examined within country.
other column(s). ⁎Pb0.05; ⁎⁎Pb0.01.
wo seasons.
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higher in British than Chinese females, and in Gambian than Chinese
males and females. 1,25(OH)2D, PTH and bone turnover markers were
higher in Gambian men and women than both British and Chinese
men and women (ANOVA P≤0.01).
Change by 2 h
On day 1, oral P loading resulted in signiﬁcant increases in P, PTH
and uP/Cr of comparable magnitude, and concurrent decreases in iCa
and uCa/Cr in all three groups, except for uCa/Cr in the British group
which was not signiﬁcantly altered (Fig. 2). On days 4 and 5, the
pattern of response was similar to that on day 1, although the
magnitude of some changes was smaller (Fig. 2). The exception was
uCa/Cr which was increased on day 5 in the Gambian group but
decreased in the Chinese group. Signiﬁcant between-group differ-
ences were found in the 2 h change in uP/Cr and uCa/Cr (Fig. 2). The
increase in uP/Cr was higher in the Chinese than in British and
Gambian subjects on days 4 and 5 (ANOVA P≤0.001) with a trend in
that direction on day 1 (ANOVA P=0.1).
The 2 h change in 1,25(OH)2D differed between the groups (Fig. 2).
In British subjects, 1,25(OH)2D was signiﬁcantly and consistently
increased after the P dose on all days. However, it was slightly
increased or remained unchanged in the Gambian, whereas in the
Chinese subjects, there was a trend for a decrease on all days (ANOVA
P≤0.001).
Signiﬁcant changes by 2 h in bone remodelling markers were
observed. OC and CTXβ increased in the British (2–4% and 8–12%
respectively, P≤0.05 on all days) and Gambian (2–5% and 2–8%
respectively, P≤0.05 on day 1) groups and non-signiﬁcant increases
in the Chinese group (3–5% and 6–10% respectively). There were no
signiﬁcant between-group differences. No signiﬁcant changes were
found in any other bone remodelling markers (P1NP, BALP, uDPD/Cr,
not shown).
Change by day 5
There was a signiﬁcant increase in fasting values of P, PTH and uP/
Cr and a concurrent decrease in iCa and uCa/Cr in the British and
Gambian subjects on day 5 in response to P loading (Fig. 3). In the
Chinese subjects, the changes in PTH, uP/Cr and uCa/Cr paralleledTable 2
Baseline plasma and urinary concentrations of calcium and phosphate, calciotropic hormon
Males
British Gambian Chinese
iCa (mg/dl) 4.72±0.12 4.68±0.12 4.68±0.12
Ca (mg/dl)a 9.28±0.36 8.60±0.56 9.52±0.44gm⁎⁎
P (mg/dl) 2.72±0.37 3.25±0.37bm⁎⁎ 3.19±0.40bm⁎
uCa/uCr 0.29±0.14 0.23±0.19 0.31±0.14
uP/uCr 1.73±0.47 1.41±0.44 1.65±0.44
25-OHD (ng/ml) 21.9±7.2 25.7±6.2 17.9±8.9gm⁎⁎
1,25(OH)2D (pg/ml) 40.1±7.8 60.3±13.1bm⁎⁎ 40.0±10.2gm⁎⁎
PTH (ng/l) 31.2 (27.8, 34.9) 45.5 (41.3, 50.0)bm⁎ 31.5 (29.3, 33.9)gm⁎
PINP (ng/ml) 34.0 (29.2, 39.5) 54.8 (48.9, 61.5) 36.0 (30.2, 42.9)
OC (ng/ml) 19.4 (17.4, 21.5) 30.6 (27.8, 33.7) 17.1 (14.5, 20.4)gm⁎
BALP (U/l) 22.3 (20.4, 24.3) 26.6 (24.4, 29.0) 23.1 (19.9, 26.9)
CTXβ (ng/ml) 0.26 (0.22, 0.32) 0.64 (0.56, 0.73)bm⁎⁎ 0.31 (0.25, 0.39)gm⁎
uDPD/uCr 5.25 (4.75, 5.79) 8.08 (7.24, 9.06) 3.53 (2.93, 4.28)bm⁎
eGFR (ml/min) 76±18.1 66±15.1 79±18.6
TmP/GFR (mg/dl) 2.49±0.55 3.12±0.52bm⁎ 2.98±0.60
Values aremean±SD or geometric means (95% conﬁdence intervals). Differences were exam
and sex differences examined within country. bm, bf, cm, cf, gm, gf next to a value indicates sig
u, urinary concentration; Ca, calcium; P, phosphorus; iCa, ionized calcium; Cr, creatinine; 25-O
propeptides of type 1 procollagen; OC, osteocalcin; BALP, bone alkaline phosphatase; βCTX,
estimated glomerular ﬁltration rate; TmP/GFR the ratio of the maximum tubular reabsorpti
All biochemical markers are presented as means of timepoint A on days 0 and 1 and are avera
and TmP/GFR that were calculated on the basis of corresponding values in blood and urine
a The comparison for pCa was adjusted for pAlbumin by including it as one of the indepethose in the other two groups, whereas P and iCa on day 5 were not
signiﬁcantly different from baseline (signiﬁcant between-group
difference ANOVA P≤0.001). The changes in iCa and PTH were
signiﬁcantly greater in the Gambian group (ANOVA P≤0.001). The
decrease in uCa/Cr was smaller in the Chinese group (ANOVA
P≤0.001). Fasting 1,25(OH)2D decreased by day 5 in all three groups,
the decrease was smaller in Gambian than in British and Chinese
subjects (ANOVA P≤0.01).
Fasting values of BALP decreased signiﬁcantly by day 5 in the
British and Gambian but not the Chinese subjects (ANOVA P=0.02).
P1NP did not change signiﬁcantly in any group. The change in OC was
greater in the Gambian than both the British and Chinese subjects
(ANOVA P≤0.01). There were no signiﬁcant changes in any of the
markers of bone resorption, except for CTXβ, which decreased in the
Chinese subjects (Fig. 4, ANOVA P≤0.001).
Regression analyses revealed that the 5-day change in PTH was
signiﬁcantly and positively related to the changes in CTXβ and OCwith
no signiﬁcant group interaction (P≤0.001 and P=0.002 respec-
tively). No signiﬁcant association with PTH was found for any of the
other markers.
Discussion
As expected, oral P stimulated PTH secretion in all British, Gambian
and Chinese subjects. However, the induced perturbations in Ca and P
homeostasis produced different responses by the kidney and skeleton.
In particular, the increase in PTH was more pronounced in the
Gambian group, and the Chinese subjects had more rapid renal P
clearance and a greater renal Ca conservation. In addition, the Chinese
subjects showed very little change in bone turnover markers, as
evidenced by fasting values on day 5, in contrast to the changes in
bone formation and/or resorption markers observed in the other
groups.
We assume that the differences in P metabolism were not due to
differences in intestinal absorption efﬁciency because dietary P is
usually well absorbed (55–80%) and plasma P increases within hours
after ingestion [19]. Indeed a signiﬁcant increase in P was observed 2 h
after the P dose in all groups. Plasma P is predominantly regulated by
changes in urinary P excretion [20] and consistent with this, uP/Cr
was increased in all three groups. However, in the Chinese subjects the
increase by 2 h was signiﬁcantly greater than in the British andes and markers of bone metabolism and kidney function indicators.
Females
British Gambian Chinese
5.04±0.16 4.88±0.2gm⁎ 4.72±0.12
9.28±0.56 9.16±0.60 9.64±0.44
3.40±0.28bm⁎⁎ 3.52±0.46 3.59±0.49
0.46±0.25 0.26±0.29bf⁎ 0.42±0.19gf⁎
2.16±0.70 1.82±0.50 1.97±0.67
25.4±5.8 29.1±7.0 18.6±6.5bf⁎,gf⁎⁎
39.1±9.5 83.8±22.4gm⁎⁎,bf⁎⁎ 45.5±9.7gf⁎⁎
33.8 (29.7, 38.4) 51.8 (46.5, 57.7)bf⁎⁎ 36.6 (32.3, 41.4)gf⁎
48.4 (43.0, 54.8) 83.6 (68.8, 101.5)bf⁎ 41.8 (37.2, 47.0)gf⁎⁎
⁎ 29.3 (26.4, 32.5) 44.7 (36.9, 54.3) 20.9 (18.7, 23.3)gf⁎
26.8 (24.9, 28.8) 37.5 (31.4, 44.9) 25.0 (22.8, 27.4)gf⁎
⁎ 0.44 (0.35, 0.47) 0.73 (0.62, 0.86) 0.42 (0.37, 0.48)
,gm⁎⁎ 8.52 (7.69, 9.42)bm⁎ 12.43 (10.95, 14.35)gm⁎ 6.36 (5.81, 6.98)cm⁎⁎,gf⁎⁎
66±25.4 67±21.6 71±16.6
2.84±0.39 3.33±0.53gm⁎ 3.90±0.77bf⁎⁎,cm⁎⁎
ined by Scheffé post-hoc tests. Country differences were examined within gender group
niﬁcant difference from counterpart(s) in other column(s). ⁎Pb0.05; ⁎⁎Pb0.01.
HD, 25 hydroxyvitamin D; 1,25(OH)2D,1,25 dihydroxyvitamin D; P1NP, total N-terminal
β form of cross-linked C-telopeptide of type 1 collagen; DPD, deoxypyridinoline; eGFR,
on rate of phosphate to glomerular ﬁltration rate.
ged over two seasons with the exception of p25-OHD that was only measured and eGFR
, respectively at timepoint A on day 0 in each season.
ndent variables in the analysis.
Fig. 2. Change by 2 h (lnBday (1, 4 or 5)− lnAday (1,4 or 5))−(lnBday 0− lnAday 0)] on days 1, 4 and 5 [% (SE)]. Black, striped and clear bars indicate British, Gambian and Chinese subjects
respectively. ⁎ = signiﬁcant change compared to baseline within country P≤0.05. b⁎ and b⁎⁎ = vs. British subjects P≤0.05 and P≤0.01 respectively; g⁎⁎ = vs. Gambian subjects
P≤0.01 by Scheffé post-hoc tests in ANOVA.
242 L. Yan et al. / Bone 45 (2009) 238–245Gambian group. This higher uP/Cr may explainwhy fasting P on day 5
was not increased in the Chinese group compared to baseline, in
contrast to the increase observed in British and Gambian subjects. We
speculate that the more rapid P clearance in Chinese subjects may be
due to differences in renal regulation of P metabolism through a
mechanism that is independent of PTH, for example ﬁbroblast growth
factor 23 (FGF23) or gastro-intestinal factors[21,22]. Plasma FGF 23 is
reported not to respond to changes in P absorptionwithin a few hours
[23]. The observed changes 2 h after P administration might rather
arise from modulation of the renal sodium-phosphate co-transporter
by the plasma P concentration and/or through at present unrecog-
nized signals involved in the phosphate intestinal-renal axis and
emanating from the gastro-intestinal tract in response to an increase
in P ingestion or absorption [22,24].
Our results may reﬂect an adaptation of the kidney and/or skeleton
to a low Ca but sufﬁcient P intake in older Chinese adults, and suggests a
mechanistic explanation for our previous ﬁndings that a higher
endogenous PTH is not associated with lower bone mineral status or
higher bone resorption [5]. The data suggest that the roles of the kidney
and skeleton in the regulation of Ca and Pmetabolismmay have shiftedtowards a greater role for the kidney, more efﬁciently clearing P and
reducing urinary Ca losses. It is impossible to tell from these data
whether this was caused by skeletal resistance to the action of PTH or
increased renal sensitivity to PTH, or to P loading. Furthermore, the
combined changes in PTH (increase) and 1,25(OH)2D (decrease) may
have resulted in preventing bone resorption or reducing bone formation
[25] in the Chinese group. A different pattern was seen in the Gambian
group. The extremely low dietary Ca intake (Table 1) is close to factorial
calculations of obligatory Ca losses in the literature [26] and may have
prevented the ‘adaptation’ seen in the Chinese group, because
maintenance of plasma Ca concentration needs fractional Ca absorption
and renal Ca conservation to be at their physiological maximum, which
requires 1,25(OH)2D to be high all the time. These different responses
may explain the differences in bone turnover markers. These remained
unchanged in the Chinese group, with the exception of CTXβ, which
showed a signiﬁcant decrease by day 5.
The 5-day increase in fasting PTH also differed between groups.
The greater decrease in iCa, and correspondingly greater increase in
PTH in the Gambian subjects may be due to their habitual
exceptionally low Ca intake and the low Ca:P ratio in the intestine
Fig. 3. 5-day change (lnA5− lnAbaseline) in fasting samples [% (SE)]. ⁎= signiﬁcant change compared to baseline within country Pb0.05. b⁎ and b⁎⁎=vs. British subjects P≤0.05 and
P≤0.01; g⁎⁎ = vs. Gambian subjects P≤0.01 by Scheffé post-hoc tests in ANOVA.
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being absorbed. The signiﬁcant decrease in BALP by day 5 in the
British and Gambian subjects may be due to inhibition of bone
formation by PTH and/or a reduction in 1,25(OH)2D, as reported in
other P and 1,25(OH)2D loading studies [27,28]. This contrasts with
the current concept of endogenous or exogenous PTH stimulating
bone formation [29] and the observed tendency of an increase in
P1NP. Potentially, this might be attributed to the different phases of
osteoblast differentiation and activation, reﬂected by these markers
[30]. The signiﬁcant increase in OC (a marker of bone formation and
potentially resorption [31]) and a tendency towards an increase in
CTXβ and uDPD/Cr in the Gambian subjects may be attributed to their
more pronounced increase in PTH.
Despite the decrease in CTXβ in the Chinese group multiple linear
regression analysis demonstrated that the changes in CTXβ and OC
were positively related to the change in PTH and that the relationships
did not differ signiﬁcantly between the groups. These ﬁndings
therefore provide no evidence in support of differences in skeletal
resistance to PTH between the groups. Our results in The Gambia are
therefore different to those in African-Americans in which skeletal
resistance to PTH was found; a smaller increase in bone resorptioncompared withWhite counterparts in response to PTH infusion [9,10].
The differences between the studies may be due to subjects' genotype,
body composition, diet, life-style and/or different methods used to
stimulate PTH secretion (PTH or citrate/Ca infusion over 24 h vs. oral P
over 5 days) [9,10]. In particular, the habitual low calcium intakes of
Gambian subjects, leading to secondary hyperparathyroidism [3,7]
and potential enlargement of the PTH reserve [32], the relatively high
Vitamin D status throughout the year and the high levels of physical
activity and low BMI in Gambians compared to African-Americans
[9,10] may have inﬂuenced these results. This was reﬂected in baseline
characteristics; Gambian subjects had elevated PTH, 1,25(OH)2D and
bone turnover markers compared to the British and Chinese subjects.
We have previously reported elevated PTH, 1,25(OH)2D and markers
of bone formation, but not resorption, in a study of Gambian women
[3], in which DPD output measured in 24 h urine samples was lower
compared to British counterparts. In the present study early morning
fasting urine samples were collected and DPD was expressed as
uDPD/Cr. Thismight, to some extent, explain the discrepancy between
our studies.
The 2 h change in 1,25(OH)2D in response to P loading was a
decrease in the Chinese, and an increase in the British and Gambian
Fig. 4. 5-day change (lnA5− lnAbaseline) in bone turnover markers [% (SE)]. ⁎ = signiﬁcant change compared to baseline within country P≤0.05. b⁎ = vs. British subjects P≤0.05;
g⁎⁎ = vs. Gambian subjects P≤0.01 by Scheffé post-hoc tests in ANOVA.
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P ﬁltration rate which suppresses 1,25(OH)2D production [33]. In
contrast, the 5-day change in 1,25(OH)2D was a decrease in all groups.
The magnitude of the decrease was signiﬁcantly smaller in the
Gambian compared to the British and Chinese subjects. This may be
due to the greater 5-day increase in PTH in the Gambian subjects
which would have had a greater stimulatory effect on renal 1-α
hydroxylase activity [12], and therefore counteracted the effect of the
increased absorbed P load.
There are some limitations to this study. Firstly, it was conducted in
subjects consuming their habitual diet. The mean Ca and P intakes in
the three groups were very different, which may have confounded the
changes in PTH and mineral metabolism in response to the same
absolute amount of P given. However, standardisation of diets across
groups would have led to deviations from habitual intake and induced
changes in ‘usual’ calcium and bone metabolism. Secondly, the range
of changes in PTH and bonemarkers inducedmay have been too small
or too short to fully evaluate skeletal responsiveness to PTH. However,the changes in plasma P and PTH were close to circadian variations
[34,35] and therefore probably correspondwith variations in plasma P,
iCa and PTH induced by diet, physical activity or circadian cycle. The
urinary excretion of Ca, P and DPDwere expressed as a ratio relative to
uCr to adjust for urine volume. Therefore, they may depend on kidney
function, lean body mass (LBM) or BMI and potentially on diet, ﬂuid
intake and sweat losses [36,37]. No signiﬁcant differences in kidney
function, as assessed by eGFR between groups were found (Table 2).
BMI was lower in Gambian subjects compared to British but not in
Chinese subjects. However, proportional LBM and sweat lossesmay be
relatively high in Gambian subjects and expected to increase rather
than decrease theuCr concentration [38].Many statistical comparisons
were reported in this study. Although Scheffé post-hoc tests were used
to minimise the effects of multiple testing, case ﬁndings may have
occurred. The main ﬁnding of this study, i.e. a difference in renal
excretion between groups, was however highly signiﬁcant (Pb0.001).
In conclusion, we have demonstrated differences in PTH secretion
and in bone and mineral metabolism in response to oral P loading
245L. Yan et al. / Bone 45 (2009) 238–245between British, Chinese and Gambian subjects, but no evidence in
support of resistance to the resorbing effects of PTH in any group.
Further investigations are in progress to explore the underlying
mechanisms for the different renal and skeletal response when Ca-P
homeostasis is perturbed and the differences in renal P clearance as
inﬂuenced by FGF23 and kidney function.
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